Researcher profile

Xiong Liu

Xiong Liu contributes to research discovery and scholarly infrastructure.

ResearcherAffiliation not importedOpen to collaborate

Trust snapshot

Quick read

Trust 19 - UnverifiedVerification L1Unclaimed author
5works
0followers
7topics
4close collaborators

Actions

Decide how to stay connected

Follow researcher0

Identity and collaboration

How to connect with this researcher

Claiming links this public author record to a researcher profile and unlocks direct collaboration workflows.

Log in to claim

Direct collaboration

Open a focused conversation when the fit is right

Claim this author entity first to unlock direct invitations.

Research graph

See the researcher in context

Open full explorer

Inspect adjacent work, topics, institutions and collaborators without jumping out to a separate graph page.

Building this graph slice

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

5 published item(s)

preprint2026arXiv

Act-Adaptive Margin: Dynamically Calibrating Reward Models for Subjective Ambiguity

Currently, most reinforcement learning tasks focus on domains like mathematics and programming, where verification is relatively straightforward. However, in subjective tasks such as role-playing, alignment techniques struggle to make progress, primarily because subjective reward modeling using the Bradley-Terry model faces significant challenges when dealing with ambiguous preferences. To improve reward modeling in subjective tasks, this paper proposes AAM (\textbf{\underline{A}}ct-\textbf{\underline{A}}daptive \textbf{\underline{M}}argin), which enhances reward modeling by dynamically calibrating preference margins using the model's internal parameter knowledge. We design two versions of AAM that efficiently generate contextually-appropriate preference gaps without additional human annotation. This approach fundamentally improves how reward models handle subjective rewards by better integrating generative understanding with preference scoring. To validate AAM's effectiveness in subjective reward modeling, we conduct evaluations on RewardBench, JudgeBench, and challenging role-playing tasks. Results show that AAM significantly improves subjective reward modeling performance, enhancing Bradley-Terry reward models by 2.95\% in general tasks and 4.85\% in subjective role-playing tasks. Furthermore, reward models trained with AAM can help downstream alignment tasks achieve better results. Our test results show that applying rewards generated by AAM-Augmented RM to preference learning techniques (e.g., GRPO) achieves state-of-the-art results on CharacterEval and Charm. Code and dataset are available at https://github.com/calubkk/AAM.

preprint2022arXiv

A general scheme of differential imaging employing weak measurement

We propose and experimentally realize a general scheme of differential imaging employing the idea of weak measurement. We show that the weak coupling between the system of interest and a two-level ancilla can introduce a two-beam circuit after an arbitrary pre-selection of the ancilla. By choosing the post-selection orthogonal to the pre-selection measurement, an effective imaging platform based on differential operations is shown achieved. Experimental results on both the Sagnac interferometer and ultra-thin Wollaston prism demonstrate that our imaging scheme successfully yields the boundary information of complex geometric configurations.

preprint2022arXiv

Customizing Knowledge Graph Embedding to Improve Clinical Study Recommendation

Inferring knowledge from clinical trials using knowledge graph embedding is an emerging area. However, customizing graph embeddings for different use cases remains a significant challenge. We propose custom2vec, an algorithmic framework to customize graph embeddings by incorporating user preferences in training the embeddings. It captures user preferences by adding custom nodes and links derived from manually vetted results of a separate information retrieval method. We propose a joint learning objective to preserve the original network structure while incorporating the user's custom annotations. We hypothesize that the custom training improves user-expected predictions, for example, in link prediction tasks. We demonstrate the effectiveness of custom2vec for clinical trials related to non-small cell lung cancer (NSCLC) with two customization scenarios: recommending immuno-oncology trials evaluating PD-1 inhibitors and exploring similar trials that compare new therapies with a standard of care. The results show that custom2vec training achieves better performance than the conventional training methods. Our approach is a novel way to customize knowledge graph embeddings and enable more accurate recommendations and predictions.

preprint2021arXiv

Applications of artificial intelligence in drug development using real-world data

The US Food and Drug Administration (FDA) has been actively promoting the use of real-world data (RWD) in drug development. RWD can generate important real-world evidence reflecting the real-world clinical environment where the treatments are used. Meanwhile, artificial intelligence (AI), especially machine- and deep-learning (ML/DL) methods, have been increasingly used across many stages of the drug development process. Advancements in AI have also provided new strategies to analyze large, multidimensional RWD. Thus, we conducted a rapid review of articles from the past 20 years, to provide an overview of the drug development studies that use both AI and RWD. We found that the most popular applications were adverse event detection, trial recruitment, and drug repurposing. Here, we also discuss current research gaps and future opportunities.

preprint2021arXiv

The impact of external innovation on new drug approvals: A retrospective analysis

Pharmaceutical companies are relying more often on external sources of innovation to boost their discovery research productivity. However, more in-depth knowledge about how external innovation may translate to successful product launches is still required in order to better understand how to best leverage the innovation ecosystem. We analyzed the pre-approval publication histories for FDA-approved new molecular entities (NMEs) and new biologic entities (NBEs) launched by 13 top research pharma companies during the last decade (2006-2016). We found that academic institutions contributed the majority of pre-approval publications and that publication subject matter is closely aligned with the strengths of the respective innovator. We found this to also be true for candidate drugs terminated in Phase 3, but the volume of literature on these molecules is substantially less than for approved drugs. This may suggest that approved drugs are often associated with a more robust dataset provided by a large number of institutes. Collectively, the results of our analysis support the hypothesis that a collaborative research innovation environment spanning across academia, industry and government is highly conducive to successful drug approvals.